Akari Therapeutics PLC（AKTX）资讯与事件AKTXAkari Therapeutics PLC

Akari Therapeutics Appoints Vatnak Vat-Ho as Chief Business Officer

Akari Therapeutics announced the appointment of Vatnak Vat-Ho as chief business officer. Most recently, Vat-Ho was chief business officer of Ryvu Therapeutics.

Akari Therapeutics Files New Patent Application

Akari Therapeutics announced the filing of PCT/US2026/45955, expanding the Company's intellectual property portfolio around its novel splicing-modulating payload, PH1 and PH1-based ADCs.

Akari Therapeutics Announces Strategic Research Collaboration with Whitehawk Therapeutics

Akari Therapeutics announced a strategic research collaboration with Whitehawk Therapeutics. Under the collaboration, the companies will conduct a series of focused preclinical studies evaluating Akari's proprietary PH1 spliceosome-modulating payload technology in combination with Whitehawk's topoisomerase I inhibitor ADC platform. Akari will lead the design, execution and evaluation of the research activities. The initial collaboration will include multiple preclinical workstreams designed to assess dual payload compatibility and synergies, while generating data intended to guide future development decisions and potential broader collaboration opportunities between the companies. The collaboration is expected to commence immediately, with interim data updates anticipated as studies progress. Both companies will jointly review resulting data and determine whether findings support broader development discussions.